13F Holdings
中文EN

PBSV Pharma-Bio Serv, Inc.

Services-Management Consulting Services · OTC · SEC CIK 1304161 · Fiscal year ends 10/31

Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.3%
TTM net income YoY398.5%
TTM EPS YoY115.1%
Revenue 3-yr CAGR-19.3%
Net income 3-yr CAGR-45.2%

Margins

Gross margin32.3%
Operating margin-1.6%
Net margin2.7%
FCF margin-4.4%
EBITDA margin-1.0%

Returns

ROE2.2%
ROA2.0%
ROIC (approx.)-1.7%
Asset turnover0.76x

Leverage & solvency

Liabilities / assets8.7%
Debt / equity0.00x
Current ratio11.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.65x
Accruals ratio5.3%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-10-31FY20242024-10-31FY20232023-10-31FY20222022-10-31FY20212021-10-31
Income statement
Revenue$9.00M$9.51M$16.98M$19.40M$20.12M
Cost of revenue$6.09M$6.99M$11.91M$14.52M$14.76M
Gross profit$2.91M$2.52M$5.07M$4.88M$5.36M
SG&A expense$3.55M$3.80M$3.95M$3.71M$9.21M
Operating income-$637,662-$1.29M$1.12M$1.17M-$3.85M
Pretax income-$94,260-$755,448$1.69M$1.19M-$1.88M
Income tax$6,203$22,171$377,307$181,679$213,246
Net income-$100,463-$777,619$1.31M$1.01M-$2.09M
EBITDA-$577,796-$1.26M$1.17M$1.23M-$3.78M
EPS (diluted)-0.00-0.030.06——
Weighted avg. shares (diluted)22.96M22.97M23.00M23.03M23.16M
Balance sheet
Cash & equivalents$3.38M$6.77M$10.45M$14.46M$17.47M
Short-term investments$7.48M$5.98M$4.53M$0—
Receivables$2.36M$2.51M$3.94M$4.98M$4.61M
Current assets$13.39M$15.70M$19.40M$19.94M$22.82M
PP&E, net$116,059$169,281$32,849$73,684$105,522
Total assets$13.65M$16.29M$19.90M$20.65M$23.92M
Current liabilities$1.74M$1.89M$2.15M$2.11M$2.67M
Total liabilities$1.74M$2.58M$3.78M$4.09M$5.01M
Shareholders' equity$11.91M$13.72M$16.13M$16.56M$18.91M
Shares outstanding22.91M22.96M22.96M22.94M23.00M
Cash flow statement
Operating cash flow-$214,886-$566,701$1.89M$592,457$804,842
Capital expenditure$6,644$159,743$7,251$19,269$10,845
Free cash flow-$221,530-$726,444$1.88M$573,188$793,997
Investing cash flow-$1.47M-$1.36M-$4.22M-$19,269$1.30M
Financing cash flow-$1.75M-$1.73M-$1.76M-$3.53M-$1.75M
Depreciation & amortization$59,866$23,311$48,086$51,107$72,728
Stock-based compensation$35,079$47,546$45,084$71,645$56,239
Dividends paid$1.72M$1.72M$1.72M$3.45M$1.73M
Share buybacks$31,443$11,263$34,344$81,992$25,966

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.